Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects

Journal of Clinical Endocrinology and Metabolism

Volumn 70, Issue 2, 1990, Pages 324-327

  Penalva A ^a   Muruais, C ^a   Casanueva, F F ^a   Dieguez, C ^a  

^a Facultad de Medicina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PYRIDOSTIGMINE; RADIOISOTOPE;

ADULT; ARTICLE; HUMAN CELL; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GROWTH HORMONE; HUMAN; MALE; PYRIDOSTIGMINE BROMIDE; RECEPTORS, MUSCARINIC; SOMATOTROPIN-RELEASING HORMONE; SUPPORT, NON-U.S. GOV'T;

EID: 0025159237     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem-70-2-324     Document Type: Article

References (19)

1. Massara F, Ghigo E, Demislis K, et al. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release studies in normal and acromegalic subjects. Neuroendocrinology 1986;43:670-5.
2. Massara F, Ghigo E, Molinatti P, et al. Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone releasing factor in man. Acta Endocrinol (Co-penh). 1986;113:12-6.
3. Ross RJM, Tsagarakis S, Grossman A, et al. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH. Clin Endocrinol (Oxf). 1987;27:727-34.
4. Penalva A, Burguera B, Casabiell X, Tresguerres JAF, Dieguez C, Casanueva FF. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycaemia on growth hormone releasing hormone induced growth hormone secretion in man: suggesting that glucose acts through hypothalamic release of somatostatin. Neuroendocrinology 1989;49:551-4.
5. Cordido F, Casanueva FF, Dieguez C. Cholinergic receptor activation by pyridostigmine restored growth hormone responsiveness after growth hormone-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. J Clin Endocrinol Metab. 1989;68:290-3.
6. Massara F, Ghigo E, Golfi S, Molinatti MG, Müller EE, Camanni F. Blockage of hp-GRF 40 induced GH release in normal men by a cholinergic muscarinic antagonist. J Clin Endocrinol Metab. 1984;59:1025-6.
7. Jordan V, Dieguez C, Lafaffian I, et al. Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29. Clin Endocrinol (Oxf). 1986;24:291-8.
8. Casanueva FF, Villanueva L, Dieguez C, et al. Atropine blockade of growth hormone releasing hormone-induced GH secretion is not exerted at pituitary level. J Clin Endocrinol Metab. 1986;62:186-91.
9. Delitala G, Palermo H, Ross R, Coy D, Besser M, Grossman A. Dopaminergic and cholinergic influences on the growth hormone response to growth hormone-releasing hormone in man. Neuroendocrinology. 1987;45:243-6.
10. Casanueva FF, Villanueva L, Cabranes JA, Cabezas-Cerrato J, Fernandez-Cruz A. Cholinergic mediation of GH secretion elicited by arginine, clonidine and physical exercise in man. J Clin Endocrinol Metab. 1984;59:526-30.
11. Delitala G, Maoili M, Pacifico A, Brianda SA, Palermo M, Manelli M. Cholinergic receptor control mechanism for L-dopa, apomor-phine and clonidine-induced growth hormone secretion in man. J Clin Endocrinol Metab. 1983;57:1145-9.
12. Penalva A, Villanueva L, Casanueva FF, Cavagnini F, Gomez-Pan A, Müller EE. Cholinergic and histaminergic involvement in the growth hormone releasing effect of an enkephalin analog FK 33824 in man. Psychopharmacology 1983;80:120-4.
13. Peters JR, Evans PI, Page MD, et al. Cholinergic muscarinic blockade with piranzepine abolishes low wave sleep-related growth hormone release in normal adult males. Clin Endocrinol (Oxf). 1986;25:213-7.
14. Piestchmann P, Schernthaner G, Luger A. Effect of cholinergic muscarinic receptor blockade on human growth hormone (GH)-releasing hormone-(l-44)-induced GH secretion in acromegalic and type I diabetes mellitus. J Clin Endocrinol Metab. 1986;63:389-92.
15. Locatelli V, Torsello A, Redaelli M, Ghigo E, Massara F, Müller EE. Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone releasing hormone in the rat: evidence for mediation by somatostatin. J Endocrinol. 1986;111:271-8.
16. Vance ML, Borges JLC, Kaiser DL, et al. Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man. J Clin Endocrinol Metab. 1984;58:838-42.
17. 2 in young adult men and women. J Clin Endocrinol Metab. 1984;59:197-201.
18. Wood SM, Ch’ng JLC, Adams EF, et al. Abnormalities of growth hormone release in response to human growth hormone releasing factor (GRF 1-44) in acromegaly and hypopituitarism. Br Med J. 1983;286:1687-90.
19. 2) dose-response effect on growth hormone and prolactin secretion in healthy adult men.Eur J Clin Pharmacol. 1986;29:609-13.